Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

NOVO-NORDISK A/S-SPONS ADR

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Health Care

Markets

AMGN

REGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Equities

News

Novo Nordisk revisa a la baja sus previsiones de crecimiento para 2025 debido a la competencia de versiones compuestas de GLP-1 en EE. UU.

Novo Nordisk (NVO) reduce previsiones de ventas 2025 por competencia de versiones compuestas

Some Speculative Stocks Can Pay Off

Small Cap

LWLG

LXRX

Una semana marcada por incertidumbres económicas reveló señales de fuerza en tres empresas de sectores clave como salud, energía e IA.

Estas 3 acciones small-cap suben hasta 60% y desafían temores de recesión e inflación persistente

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

Making weight loss injections available to all eligible individuals in the U.K. could yield an economic boost of 4.5 billion pounds (around $5.99 billion) annually, according to new research presented at the European Congress <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">on Obesity in Málaga, Spain</a>.
The findings highlight the broader societal and productivity benefits of Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide, a drug known by brand names such as Wegovy and Ozempic.
Globally, obesity is projected to affect 3.8 billion adults and nearly 750 million children and adolescents by 2050.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
In the U.K., 26.5% of adults are currently obese, and 4.6 million people live with type 2 diabetes. These conditions cost the U.K. an estimated 100 billion pounds annually in healthcare and related expenses, according to the Guardian report.
The study examined data from 2,660 participants in U.K. clinical trials who were living with obesity and/or type 2 diabetes.
Researchers found that those taking semaglutide could work five additional days per year and contribute 12 extra days of unpaid labor, such as volunteering or childcare.
This increase in productivity translated to an average annual &#8220;net production value&#8221; of 1,127 pounds per person.
Applied nationally, the researchers estimated potential productivity gains of 4.31 billion pounds from treating individuals with severe obesity and 200 million pounds from treating those with type 2 diabetes.
Currently, NHS guidelines recommend semaglutide for patients with a BMI of 35 or higher and at least one weight-related condition.
However, some experts cautioned against widespread access due to high drug costs.
The U.K. Health Secretary Wes Streeting acknowledged the findings, calling the drugs &#8220;colossal&#8221; tools in the fight against obesity and a potential means to reintegrate unemployed Britons into the workforce. He said the government would carefully assess the research.
Semaglutide and liraglutide may also have implications beyond weight loss.
Citing another study presented at the Málaga conference, the Guardian <a target="_blank" href="https://www.theguardian.com/society/2025/may/09/weight-loss-jabs-bolster-uk-economy-study-semaglutide" rel="noreferrer noopener">report</a> on Friday highlighted that overweight adults taking the drugs cut their alcohol consumption by nearly two-thirds in just four months.
The study tracked 262 individuals in Ireland and Saudi Arabia and reported a drop in weekly alcohol intake from 11.3 to 4.3 units. Among regular drinkers, consumption fell from 23.2 to 7.8 units—an effect greater than that seen with nalmefene, a drug currently prescribed in Europe for alcohol use disorder.
Price Action: NVO stock is down 1.67% at $64.31 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45411513/kraft-heinz-bets-3-billion-on-us-factory-overhaul-to-offset-tariff-impact-report" target="_blank" rel="noreferrer noopener">Kraft Heinz Bets $3 Billion On US Factory Overhaul To Offset Tariff Impact: Report</a></li>
</ul>
Photo by KK Stock via Shutterstock

Biotech

Large Cap

Eurozone

General

Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds

Septerna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced an exclusive global collaboration and license agreement on Wednesday.
The pact covers discovering, developing, and commercializing oral small-molecule medicines for obesity, type 2 diabetes, and other <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cardiometabolic diseases</a>.
The companies <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916006" target="_blank" rel="noreferrer noopener">will</a> initially commence four development programs. 
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45347237/novo-nordisks-sogroya-supports-effective-weekly-alternative-to-daily-hormone-therapy-across-three-growth-disorders" rel="noreferrer noopener">Novo Nordisk&#8217;s Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders</a>
GPCRs represent the largest and most diverse family of cell membrane receptors, with hundreds of different GPCRs regulating physiological processes in nearly every organ system of the human body.
Using its proprietary Native Complex Platform, Septerna aims to unlock the full potential of GPCR therapies. The company is focused on discovering and developing a pipeline of oral small molecules for multiple therapeutic areas.
Septerna is eligible to receive approximately $2.2 billion across an upfront payment, R&amp;D, and commercial milestone payments. It also includes over $200 million in upfront and near-term milestone payments.
Septerna can also receive tiered royalties on global net sales of marketed products. Under the collaboration, Novo Nordisk will cover all research and development expenses for partnered programs.
The companies will jointly conduct research activities from discovery through candidate selection.
Starting with IND-enabling activities, Novo Nordisk will be solely responsible for all global development and commercialisation activities. In addition, Septerna has the right to opt in to a worldwide profit share for one program in the collaboration in lieu of future milestones and royalties for that product candidate.
On Tuesday, secondary post hoc <a target="_blank" href="https://www.prnewswire.com/news-releases/in-new-select-trial-analysis-early-reduction-in-cardiovascular-events-was-observed-with-wegovy-before-clinically-meaningful-changes-in-body-weight-302453751.html" rel="noreferrer noopener">analysis</a> of Novo Nordisk&#8217;s SELECT trial showed that within the first three months of Wrgovy treatment, reductions in the risk of MACE in adults with obesity and established cardiovascular disease (CVD) were seen.
Reductions were also observed within six months in the risk of dying from CVD or being hospitalized or needing urgent medical attention due to heart failure.
Data showed that within six months of treatment, a reduction in risk of CV death was observed for patients taking Wegovy&nbsp;related to CV death; lowered composite heart failure risk, and reduced death from any cause.
Price Action: Septerna stock is up 63.08% at $10.98. Novo Nordisk stock is up 1.87% at $66.62 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii&#8217;s Plavix Lawsuit</a></li>
</ul>
Image: Shutterstock

Contracts

Movers

Trading Ideas

SEPN

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) and Novo Nordisk today announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases.
The companies will initially commence four development programmes for potential small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, including the GLP-1, GIP and glucagon receptors.
&nbsp;
<ul>
<li>Septerna is eligible to receive approximately 2.2 billion US dollars, including more than 200 million dollars in upfront and near-term payments</li>
</ul>

Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

WIIM

Shares of pharmaceutical stocks are trading lower amid President Trump's drug pricing executive order.

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya&nbsp;(somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short stature (ISS) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">under one trial protocol</a>.
In REAL8, pre-pubertal children with NS, TS, or ISS were randomized to receive either once-weekly Sogroya&nbsp;(somapacitan) 0.24 mg/kg/week or once-daily somatropin 0.050 mg/kg/day.
Children born SGA were <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916003" rel="noreferrer noopener">randomized</a> to receive either somapacitan 0.24 mg/kg/week, a low dose of somatropin 0.035 mg/kg/day, or a high dose of somatropin 0.067 mg/kg/day.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin&nbsp;(somatropin) in improving yearly growth rate (as measured by height velocity or HV at Week 52).
In addition, once-weekly Sogroya was superior to daily growth hormone in children with NS and to lower doses of daily growth hormone in children born SGA.
REAL8 data showed that Sogroya&nbsp;was well-tolerated, with no safety or tolerability issues identified compared to once-daily growth hormone.
Results from the Turner syndrome (TS) sub-study of REAL8 will be available later this year.
The REAL8 trial achieved its primary endpoints for the first three sub-studies, demonstrating that once-weekly Sogroya&nbsp;was non-inferior to once-daily growth hormone treatment at Week 52 across the three indications presented:
<ul class="wp-block-list">
<li>In children born SGA, Sogroya&nbsp;demonstrated superior estimated mean HV when compared with a lower dose (0.035 mg/kg/day) of somatropin (11.0 vs 9.4 cm/year) and non-inferior estimated mean HV when compared with a higher dose (0.067 mg/kg/day) of somatropin (11.0 vs 11.1 cm/year).</li>
<li>Sogroya&nbsp;demonstrated superior estimated mean HV in children with NS compared with somatropin (10.4 vs 9.2 cm/year).</li>
<li>Sogroya&nbsp;demonstrated non-inferior estimated mean HV in children with ISS compared with daily somatropin (10.5 vs 10.5 cm/year).</li>
<li>In April 2025, based on the data from REAL8 and REAL9, the three indications (SGA, NS, and ISS) were submitted for regulatory review in both the EU and the U.S.</li>
</ul>
Price Action: NVO stock is down 3.00% to $63.80 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path" target="_blank" rel="noreferrer noopener">Shopify Shows Strong Global Momentum, But Guidance Raises Questions On Profitability Path</a></li>
</ul>
Image via Shutterstock

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk&#8216;s stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.
What Happened:&nbsp;Cuban criticized Kirk&#8217;s&nbsp;focus on Big Pharma as&nbsp;the primary driver of high drug prices. Instead, Cuban pointed to PBMs as the major offenders&nbsp;due to their opaque pricing&nbsp;practices and market dominance. Cuban highlighted the lack of transparency in PBMs&#8217; contracts, which often prohibit disclosing pricing details. He challenged&nbsp;Kirk to obtain a net&nbsp;price list from his company&#8217;s PBM. 
Meanwhile, Charlie Kirk, the founder of Turning Point USA, has regularly raised questions on the practices of Big Pharma through his posts and podcasts.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Charlie , you aren&#39;t close. Drug prices are too damn high. But the big culprit isn&#39;t the brand manufacturers, it&#39;s the big middlemen. Namely PBMs. They work so hard to distort pricing the first lines in their contracts with everyone is &quot;you can&#39;t disclose any of this &quot; How bad… <a href="https://t.co/oMnlvlOPtl">https://t.co/oMnlvlOPtl</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1921755430708969767?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban&#8217;s post aligns&nbsp;with a 2022 FTC investigation&nbsp;into PBMs&#8217;&nbsp;role in rising drug costs&nbsp;through practices like spread pricing. Moreover, according to a 2023 Bipartisan&nbsp;Policy Center, six PBMs control&nbsp;95% of the private market. 
He supports Trump's Executive Order to lower drug prices by 30-80%, suggesting that targeting PBMs, such as separating formularies and mandating claim disclosures, could make brand medications cheaper than in many countries, building on his own efforts with Cost Plus Drugs to cut out middlemen and reduce costs.
In one of his initial responses, Mark Cuban expressed support for the move, stating it could &#8220;force transparency,&#8221; even if the President can&#8217;t mandate price reductions.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/05/45338281/trump-has-a-proven-track-record-of-being-an-absolute-failure-says-gov-tim-walz-we-dont-need-to-run-governmen" target="_blank" rel="noreferrer noopener">Trump Has A &#8216;Proven Track Record Of Being An Absolute Failure,&#8217; Says Gov. Tim Walz—&#8217;We Don&#8217;t Need To Run Government Like A Business&#8217;</a>
Why It Matters: Cuban&#8217;s comments come in the wake of President Donald Trump&#8216;s announcement of a sweeping executive order aimed at slashing prescription drug prices. The order, which Trump referred to as the &#8220;most consequential executive order&#8221; in U.S. history, is set to implement a &#8220;Most Favored Nations&#8221; <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">policy requiring</a> pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country.
Cuban, despite being a Trump critic, has <a href="https://benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">expressed support</a> for Trump&#8217;s healthcare order, emphasizing its potential to reform the role of PBMs in the U.S. healthcare system and save billions. He believes&nbsp;that targeting PBMs—such as separating&nbsp;formularies and mandating claim disclosures—could&nbsp;make brand medications cheaper than&nbsp;in many countries.
Meanwhile, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were trading 2% to 5% lower in Monday&#8217;s premarket in response to Trump&#8217;s executive order.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45328061/bitcoin-ethereum-xrp-dogecoin-enter-weekend-strong-long-dips-140000-is-programmed-trader-says" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Enter Weekend Strong: &#8216;Long Dips, $140,000 Is Programmed,&#8217; Trader Says &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company…Ask Your PBM For A List Of Claims'

<ul>
<li>The REAL8 trial showed that after 52 weeks, once-weekly Sogroya (somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin (somatropin) in children born small for gestational age (SGA)1, or with Noonan syndrome (NS)2, or with idiopathic short stature.</li>
<li>Superiority was achieved for once-weekly somapacitan versus daily growth hormone in children with NS2, as well as compared to lower doses of daily growth hormone in children born SGA1.</li>
<li>These conditions are often associated with significant health challenges and a high treatment burden from daily injections, which can lead to a lack of adherence and put successful treatment outcomes at risk. Novo Nordisk is committed to bringing our expertise and scientific innovation to help improve the lives of children with conditions that impact their growth.</li>
</ul>

Novo Nordisk Presented Data From Phase 3 REAL8 Basket Study, Which Showed That Once-weekly Sogroya (Somapacitan) Was Non-inferior To The Once-daily Growth Hormone Norditropin (Somatropin) In Improving Yearly Growth Rate In Children With Growth Disorders

On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the &#8220;<a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">most consequential executive order</a>&#8221; in U.S. history, aimed at lowering prescription drug prices.
What Happened: Trump said the executive order, set to be signed at 9 a.m. Monday, will implement a &#8220;Most Favored Nations&#8221; policy requiring pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country.
See More: <a href="https://www.benzinga.com/25/05/45338985/trump-reportedly-set-to-accept-flying-palace-from-qatar-white-house-says-lavish-gift-of-boeing-jumbo-jet-complies-with-all-applicable-laws">Trump Reportedly Set To Accept &#8216;Flying Palace&#8217; From Qatar, White House Says Lavish Gift Of Boeing Jumbo Jet Complies With &#8216;All Applicable Laws&#8217;</a>
Accusing pharmaceutical companies of overcharging American consumers, sometimes &#8220;five to ten times more&#8221; than patients in other countries, Trump slammed political opponents for enabling the status quo all these years.
Trump says that prescription drug prices will be reduced by &#8220;30% to 80%,&#8221; while rising throughout the world, to equalize and &#8220;bring fairness to America.&#8221;
Why It Matters: This move is expected to have the biggest impact on Medicare Part B drugs, which mainly constitute outpatient prescriptions and biologicals, the prices for which are directly managed by the Centers for Medicare &amp; Medicaid Services (CMS).
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th class="has-text-align-center" data-align="center">Drug Name</th>
<th class="has-text-align-center" data-align="center">Manufacturer(s)</th>
<th class="has-text-align-center" data-align="center">Total Spending</th>
<th class="has-text-align-center" data-align="center">Primary Use</th>
</tr>
</thead>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Keytruda</td>
<td class="has-text-align-center" data-align="center">Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td class="has-text-align-center" data-align="center">$4.0B</td>
<td class="has-text-align-center" data-align="center">Cancer (various types)</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Eylea</td>
<td class="has-text-align-center" data-align="center">Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) </td>
<td class="has-text-align-center" data-align="center">$3.4B</td>
<td class="has-text-align-center" data-align="center">Macular degeneration</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Prolia/Xgeva</td>
<td class="has-text-align-center" data-align="center">Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td class="has-text-align-center" data-align="center">$2.1B</td>
<td class="has-text-align-center" data-align="center">Osteoporosis, bone metastases</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Opdivo</td>
<td class="has-text-align-center" data-align="center">Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) </td>
<td class="has-text-align-center" data-align="center">$2.0B</td>
<td class="has-text-align-center" data-align="center">Cancer (various types)</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Darzalex</td>
<td class="has-text-align-center" data-align="center">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td class="has-text-align-center" data-align="center">$1.9B</td>
<td class="has-text-align-center" data-align="center">Multiple myeloma</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Avastin</td>
<td class="has-text-align-center" data-align="center">Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)</td>
<td class="has-text-align-center" data-align="center">$1.8B</td>
<td class="has-text-align-center" data-align="center">Cancer (various types)</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">A breakdown of the top Medicare Part B drugs by spending in 2023, based on the latest data shared by the Centers for Medicare &amp; Medicaid Services (CMS).</figcaption></figure>
These are the stocks that are most likely to be hit by this announcement when markets open on Monday, given their sizable exposure to Medicare, especially being classified as Part B. 
According to a report by the Rand Corporation, a California-based policy think-tank, prescription drug prices in the U.S. are, on average, at least 2.78 times higher than other countries.
While Trump&#8217;s move is being criticized by the likes of crypto enthusiast Ed Krassenstein, calling it &#8220;just another Trump lie,&#8221; saying that an executive order can steer Medicare and Medicaid payments, but <a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">cannot force manufacturers</a> to cut prices. 
Others, such as billionaire investor Mark Cuban, have come out in support of the move, saying that it can &#8220;force transparency,&#8221; even if the President cannot force price cuts.
Drug pricing disparities have been a point of contention across the political spectrum. Recently, Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) CEO, Lars Fruergaard Jorgensen, <a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on">faced Senate scrutiny</a> on these vast differences, where he was targeted by Sen.&nbsp;Bernie Sanders&nbsp;(I-Vt.) for the high price of the company&#8217;s diabetes drug, Ozempic. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="135" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12033045/Screenshot-2025-05-12-at-1.00.28-PM-1024x135.png" alt="" class="wp-image-911404" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12033045/Screenshot-2025-05-12-at-1.00.28-PM-1024x135.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12033045/Screenshot-2025-05-12-at-1.00.28-PM-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12033045/Screenshot-2025-05-12-at-1.00.28-PM-768x101.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12033045/Screenshot-2025-05-12-at-1.00.28-PM-1536x202.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12033045/Screenshot-2025-05-12-at-1.00.28-PM.png 1594w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Novo Nordisk shares have an unfavorable price trend in the short, medium, and long term, but how does it compare with peers such as Johnson &amp; Johnson, Amgen, and Roche? Sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a> to find out.
Meanwhile, Novo Nordisk, Pfizer and J&amp;J were trading at least 3% lower in Monday premarket. 
Photo Courtesy: create jobs 51 On Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45339784/mohamed-el-erian-warns-us-china-deal-reveals-americas-fear-of-empty-shelves-as-markets-rally-on-trade-optimism-peter-schiff-skeptical-without-renminbi-revaluation">Mohamed El-Erian Warns US-China Deal Reveals &#8216;America&#8217;s Fear Of Empty Shelves&#8217; As Markets Rally On Trade Optimism, Peter Schiff Skeptical Without Renminbi Revaluation</a></li>
</ul>

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket

Eli Lilly and Company&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy in a 72-week head-to-head trial.
What Happened: Participants treated with tirzepatide (Zepbound) achieved an average weight loss of 20.2%, compared to 13.7% with semaglutide (Wegovy), representing a 47% greater relative weight reduction, according to detailed results from a direct comparison trial published in The New England Journal of Medicine. 
On average, those taking Zepbound lost 50.3 pounds, while those on Wegovy lost 33.1 pounds over the course of the study.
The SURMOUNT-5 Phase 3b open-label clinical trial met its primary endpoint and all five key secondary endpoints, with Zepbound showing superiority across all weight reduction targets. Nearly 65% of Zepbound users achieved at least 15% weight loss compared to 40% on Wegovy, and participants experienced greater waist circumference reduction —7.2 inches versus 5.1 inches.
The safety profile aligned with previous trials, with primarily gastrointestinal-related adverse events that were generally mild to moderate in severity. Discontinuation rates due to adverse events were 6.1% for Zepbound versus 8% for Wegovy.
See Also: <a href="https://www.benzinga.com/25/05/45340117/peter-lynch-said-the-suckers-going-up-is-no-buy-strategy-suggests-two-things-to-look-for-in-a-company-that-suggest-something-different">Peter Lynch Once Lamented People Are &#8216;Careful&#8217; When They Buy A Fridge But Will &#8216;Drop Thousands&#8217; On A Stock Tip They Heard On A Bus</a>
Why It Matters: Zepbound&#8217;s performance in this direct comparison strengthens Lilly&#8217;s position in the rapidly growing weight loss medication market. The drug operates as a dual GIP and GLP-1 receptor agonist, compared to Wegovy, which works solely as a GLP-1 receptor agonist.
The U.S. Food and Drug Administration recently expanded Zepbound&#8217;s approval to include <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">treatment for moderate-to-severe obstructive sleep apnea</a> in adults with obesity. Clinical trials showed patients experienced an average of 25 fewer breathing interruptions per hour, with up to 50% no longer exhibiting OSA symptoms after one year.
WW International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) recently announced a <a href="https://www.benzinga.com/news/25/04/45073094/weightwatchers-integrates-with-eli-lilly-to-expand-access-to-zepbound-stock-skyrockets-110">partnership with LillyDirect</a> pharmacy provider Gifthealth to simplify access to Zepbound for eligible self-pay clinic members. According to WeightWatchers, 33% of its clinic patients currently use Zepbound as part of their weight management plan, with prescriptions more than doubling in recent months.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45339966/bitcoin-creator-satoshi-nakamotos-estimated-wealth-crosses-bill-gates-amid-apex-cryptos-sharp-rebound">Bill Gates Left Behind By Satoshi Nakamoto: Bitcoin Creator&#8217;s Wealth Now Eclipses That Of Microsoft Co-Founder Amid Crypto&#8217;s Sharp Rebound</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

On Sunday, President Donald Trump vowed to <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">slash prescription drug prices</a> through a sweeping executive order.
What Happened: Trump took to Truth Social and announced plans to sign a new executive order. Under what he called a "most favored nation" pricing policy, the President said the executive order will ensure that "the United States will pay the same price as the Nation that pays the lowest price anywhere in the World."
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="612" height="966" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22.png" alt="" class="wp-image-911175" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22.png 612w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22-190x300.png 190w" sizes="(max-width: 612px) 100vw, 612px" /></figure>
Screenshot From President Donald Trump&#8217;s Truth Social Account
He added that prescription drug prices would drop "almost immediately, by 30% to 80%," and called the move "one of the most consequential Executive Orders in our Country's history."
In response, a user on X, formerly Twitter, expressed skepticism, saying, "It would be nice if Trump&#8217;s super important post about drug prices was really achievable. I think all Democrats would agree&#8230; But like most things Trump brags about, they are pie-in-the-sky promises that can&#8217;t and won&#8217;t actually materialize."
See Also: &nbsp;<a href="https://benzinga.com/news/25/04/44935195/elizabeth-warren-says-if-trump-illegally-fires-fed-chair-powell-hell-crash-our-markets-cause-more-economic-p" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says, ‘If Trump Illegally Fires Fed Chair Powell, He'll Crash Our Markets, Cause More Economic Pain To American Families'</a>
That's where <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">billionaire entrepreneur</a> and Cost Plus Drugs founder Mark Cuban stepped in. Cuban acknowledged the ambition of Trump's plan but highlighted a more attainable path forward.
"I don't know if he can force the price, but he can force transparency, and that will help," Cuban wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I dont know if he can force the price , but he can force transparency , and that will help. He did it w hospitals Force transparency of contracts, pricing , rebates , claims and a lot could change Biggest thing he could do is encourage brand pharma to sell to cost plus drugs… <a href="https://t.co/vkz3Q2IFkn">https://t.co/vkz3Q2IFkn</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1921710702743417149?ref_src=twsrc%5Etfw">May 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It's Important: Last month, Trump issued a <a href="https://benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">multi-part executive order</a> targeting drug pricing transparency and Medicare cost reduction.
Earlier this month, he signed <a href="https://www.benzinga.com/news/25/05/45232993/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites">another executive order directing</a> the Food and Drug Administration to expedite approvals for domestic pharmaceutical manufacturing facilities.
The Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) and iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) rose 2.61% and 2.81%, respectively, over the past month.
Price Action: In after-hours trading, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was up 0.20%, while Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) increased by 0.32% and 0.13%, respectively. Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also saw a modest gain of 0.12%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Photo Courtesy: PeopleImages.com &#8211; Yuri A On Shutterstock.com
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing" target="_blank" rel="noreferrer noopener">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'

<h2 class="wp-block-heading">New On The Block</h2>
Nestlé (SWX: NESN) is trying to offload its premium bottled water biz—including Perrier and S.Pellegrino—for a thirst-quenching 5 billion euros ($5.6 billion), and it's tapped Rothschild to play matchmaker. Reuters, which broke the news, reports that Nestle wants to keep a stake. 
The move comes amid some political backwash in France. Authorities just <a href="https://www.lemonde.fr/en/france/article/2025/05/08/perrier-ordered-to-remove-water-filters_6741040_7.html">told</a> Nestlé to yank microfilters from two Perrier plants, raising eyebrows and maybe a few pH levels. 
Enter One Rock Partners. The firm, which previously helped extract Poland Springs from Nestlé in 2021 and now owns Primo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>), is expected to make an offer. 
The deal comes as water scarcity intensifies globally. According <a href="https://www.worldwildlife.org/stories/water-scarcity-8-facts-you-need-to-know">to</a> the World Wildlife Fund, over two billion people lack safe drinking water, and some projections show up to 2.4 billion facing urban shortages by 2050.
Other companies up for sale include:
<ul class="wp-block-list">
<li>Hellman &amp; Friedman has kicked off a sale process for Enverus, a Texas-based energy software firm. The deal is expected to fetch around $6 billion. The private equity firm is working with Citi on the sale, which Reuters reports has drawn interest from both other PE firms and strategic buyers.</li>
</ul>
<ul class="wp-block-list">
<li>Speedcast is exploring the sale of its ground stations business. The transaction price could exceed $1 billion, according <a href="https://www.bloomberg.com/news/articles/2025-05-08/speedcast-is-said-to-mull-breakup-sale-of-ground-stations-unit?srnd=phx-deals&amp;sref=TBDibEcD">to</a> Bloomberg. Backed by Centerbridge Partners, the Houston-based satellite communications firm is working with an adviser and plans to run three separate auctions covering its services, infrastructure and government-focused units. Speedcast's ground stations enable it to deliver internet via satellite to clients like cruise lines and maritime shippers across its five business segments.</li>
</ul>
<ul class="wp-block-list">
<li>UBS Group AG is in talks to sell its hedge fund unit, O'Connor, to Cantor Fitzgerald LP, after over 30 years of ownership. The deal may include a revenue-sharing agreement, allowing UBS to receive a portion of future proceeds, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-05-08/ubs-in-talks-to-sell-hedge-fund-o-connor-to-cantor-fitzgerald?sref=TBDibEcD">reported</a>. This move comes as UBS looks to shed riskier assets in light of stricter Swiss regulations that could require up to $25 billion in additional capital. O'Connor, originally a Chicago-based derivatives firm acquired in 1992, had $16.5 billion in regulatory assets under management as of December.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul class="wp-block-list">
<li>OpenAI has agreed to buy Windsurf, an artificial intelligence-assisted coding tool, for about $3 billion, <a href="https://www.bloomberg.com/news/articles/2025-05-06/openai-reaches-agreement-to-buy-startup-windsurf-for-3-billion?sref=TBDibEcD">reported</a> Bloomberg. The deal hasn't closed yet. If successful, it positions OpenAI to better compete in the growing market for AI-powered coding assistants, where rivals like Anthropic, GitHub, and newer startups like Anysphere are gaining traction. Windsurf, also known as Exafunction Inc. and previously as Codeium, was recently valued at <a href="https://www.benzinga.com/25/05/45224667/microsoft-backed-openai-buys-windsurf-for-3-billion-to-strengthen-ai-coding-power">$3 billion</a>.</li>
</ul>
<ul class="wp-block-list">
<li>VivoPower International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) announced that Energi Holdings has completed the first phase of due diligence for its proposed $180 million takeover. Energi, a global energy firm based in Abu Dhabi with $1 billion in annual revenue, will now move to an accelerated second phase focused on regulatory matters. Folks involved expect the deal to conclude by June 2.</li>
</ul>
<ul class="wp-block-list">
<li>Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) is <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45287050/coinbase-acquires-deribit-in-2-9b-deal-to-expand-crypto-derivatives-business">acquiring crypto options exchange</a> Deribit in a $2.9 billion cash-and-stock deal, aiming to become the largest crypto derivatives platform by open interest and volume. The deal includes $700 million in cash and 11 million Coinbase Class A shares. It&#8217;s expected to close by year-end, pending regulatory approval. Deribit processes over $1 trillion in annual trading volume and has $30 billion in open interest, mainly from institutional clients. This is the latest in a string of acquisitions by Coinbase. It follows past purchases like Xapo (custody), Tagomi (prime brokerage), FairX (futures exchange) and One River Digital (asset management).</li>
</ul>
<ul class="wp-block-list">
<li>Pershing Square's Bill Ackman wants to turn Howard Hughes Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) into a <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43799342/bill-ackman-following-warren-buffett-hedge-funder-promises-modern-day-berkshire-hathaway-with-latest-transaction">&#8220;modern-day Berkshire Hathaway.&#8221;</a> On Monday, Pershing Square announced plans to invest $900 million in the real estate company Howard Hughes. Ackman&#8217;s firm will purchase 9 million shares for $100 each, representing a stake of 46.9%. The investment will allow Howard Hughes to acquire controlling stakes in companies while continuing to invest in <a href="https://www.benzinga.com/25/05/45199902/bill-ackman-strikes-deal-to-form-mini-version-of-berkshire-hathaway-a-free-money-generating-company-he-wouldnt-bet-against">real estate</a>.</li>
</ul>
<h2 class="wp-block-heading">Off The Block</h2>
<ul class="wp-block-list">
<li>WhiteHawk Income Corp. will acquire PHX Minerals Inc. in a deal that values PHX at about $187 million including debt. The acquisition adds 1.8 million gross unit acres of natural gas mineral and royalty assets to WhiteHawk. It also enters the SCOOP/STACK region in Oklahoma.</li>
</ul>
<ul class="wp-block-list">
<li>FiscalNote Holdings Inc. agreed<a href="https://www.benzinga.com/pressreleases/25/05/b45190351/fiscalnote-signs-definitive-agreement-to-divest-additional-non-core-asset-to-further-streamline-co" target="_blank" rel="noreferrer noopener"> to sell</a> its Australian subsidiary, TimeBase, to Thomson Reuters Corporation. FiscalNote acquired TimeBase in 2021. The divestiture is part of FiscalNote&#8217;s effort to streamline operations, reduce debt, and refocus on its core strengths—particularly the enhanced PolicyNote platform, which will continue serving clients in the Australian market. Proceeds from the sale will be used to pay down the <a href="https://www.benzinga.com/25/05/45197222/fiscalnote-sells-timebase-to-thomson-reuters-for-65m-as-it-sharpens-focus-and-reaffirms-2025-outlook">company&#8217;s senior-term loan</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) agreed to acquire Parkland Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PKIUF#OTC">PKIUF</a>) in a deal valued at approximately $9.1 billion, including debt. The transaction, announced Monday, <a href="https://www.benzinga.com/pressreleases/25/05/n45190343/sunoco-lp-to-acquire-parkland-corporation-in-transaction-valued-at-9-1-billion">involves a mix of cash and equity </a>and will create a new entity called Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>). Shares were <a href="https://www.benzinga.com/premarket">trading lower</a> on Monday after the company agreed to acquire Parkland Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PKIUF#OTC">PKIUF</a>) in a deal valued at approximately $9.1 billion, including debt. SUNCorp, LLC. Parkland operates as a major fuel distributor and convenience retailer across 26 countries in the Americas. With around 4,000 locations, it serves consumers and businesses with fuel and energy solutions, including renewables, EV charging and <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45194533/sunoco-fuels-up-with-9-1b-parkland-deal-eyes-10-cash-flow-bump">carbon credit options</a>.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) just put its financial strategy on a strict plan of its own. The company, known as WeightWatchers, announced a "pre-packaged" Chapter 11 reorganization that will eliminate a chunky $1.15 billion in debt. The goal? To slim down its liabilities and sprint toward long-term growth—no crash diets involved.
WeightWatchers insists it's business as usual. Members won't notice a thing—no plan changes or vanishing telehealth sessions. The company's holistic model (including doctor-recommended programs and prescription support) stays fully operational during the reorganization.
Backed by 72% of its lenders, the 62-year-old brand expects a speedy exit in about 45 days—faster than most people's post-holiday detox.
CEO Tara Comonte says this financial cleanse is all about building muscle for innovation, with a focus on digital upgrades and expanding WW&#8217;s fast-growing telehealth biz, which bulked up by 57% in Q1 2025 alone.
Weight loss drugs like Ozempic and Wegovy, both from Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), likely disrupted WeightWatchers&#8217; traditional business model.
<a href="https://www.benzinga.com/ma/25/05/45177095/deal-dispatch-chef-boyardee-crumbl-buyers-bankruptcies">For last week&#8217;s edition of Deal Dispatch, click here</a>.

Tech

COIN

PKIUF

PRMB

VVPR

Deal Dispatch: Nestlé, Coinbase, OpenAI Lead Diverse M&A Lineup As WeightWatchers Goes Bankrupt

If short sellers were hoping for a flop from Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), they may want to check their risk management settings. The telehealth disruptor dropped <a href="https://www.benzinga.com/earnings">first-quarter earnings</a> after the bell on Monday, and instead of the crash shorts were counting on, the market got a bullish cocktail: strong guidance, solid revenue growth and a headline-making partnership with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Shares popped &#8211; and they&#8217;ve kept climbing.
Read Also: <a href="https://www.benzinga.com/news/25/05/45262023/hims-hers-stock-soars-32-since-tuesday-on-strong-q1-earnings-and-robust-outlook">Hims &amp; Hers Stock Soars 32% Since Tuesday On Strong Q1 Earnings And Robust Outlook</a>
<h2 class="wp-block-heading">HIMS Stock Up 100% In A Month</h2>
HIMS is now up 100% in the past month and more than 100% year-to-date, defying bears who bet on a post-compounding hangover after the FDA signaled the end of semaglutide shortages.
Short interest remains stubbornly high &#8211; about 33% of the float, per NYSE data. That's a significant chunk of the stock sitting in borrowed hands, and every uptick tightens the squeeze.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0508"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08120423/Screenshot-2025-05-08-at-9.33.01-PM.png" alt="" class="wp-image-908485" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08120423/Screenshot-2025-05-08-at-9.33.01-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08120423/Screenshot-2025-05-08-at-9.33.01-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0508" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The technicals are no help to the pessimists. HIMS trades at $51.12, well above its eight-day, 20-day, 50-day, and even 200-day moving averages—a strong bullish trend by any measure.
This might already be the start of a classic short squeeze: earnings didn't break the bull run, and instead of pulling back, the stock gained even more traction. That means shorts sitting on losses are either holding out for a miracle or quietly covering before things get worse.
The bears may have been early &#8211; but if this trend holds, they're about to be steamrolled. Hims &amp; Hers isn't just selling weight-loss meds anymore… it might be handing out humble pie.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45282981/top-3-health-care-stocks-that-could-sink-your-portfolio-in-q2">Top 3 Health Care Stocks That Could Sink Your Portfolio In Q2</a></li>
</ul>
Photo: Shutterstock

Short Sellers

Short Ideas

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are <a href="https://www.benzinga.com/etfs">closely watching pharmaceutical ETFs</a> to measure market sentiment and ride out the emerging volatility. 
With President Donald Trump&#8217;s administration rehashing contentious ideas on drug pricing and manufacturing policy, the stakes are increasing — not only for Big Pharma, but for the overall healthcare investment environment.
Amid the trends, pharma-targeted ETFs are being watched under a more risk-averse lens. Each of the funds provides sector exposure, but structural idiosyncrasies — and varying levels of protection from regulation-induced shocks — are gaining heightened relevance.
<h1 class="wp-block-heading">Slicing Up The Pharma ETF Scene</h1>
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
The ETF offers concentrated exposure to large-cap U.S.-listed pharma companies. Its top holdings are Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) — companies with strong pipelines and international revenue streams.
Defensive Tilt: IHE&#8217;s emphasis on blue-chip names makes it a relatively defensive play during periods of political unrest.
Policy Sensitivity: But its large weighting in companies with substantial Medicaid and U.S. sales exposure renders it highly sensitive to pharmaceutical pricing reform in the domestic market.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
Unlike IHE, the SPDR S&amp;P Pharmaceuticals ETF uses an equal-weighting style, dispersing exposure across a larger segment of the industry, including mid- and small-cap companies such as Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>).
Diversified Risk: This format caps overconcentration in a single name and increases sensitivity to prospective M&amp;A action.
Higher Volatility: As more importance is assigned to lesser-known participants, XPH can see greater price volatility, particularly as regulatory threats play out.
VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)
Those in search of global exposure should look at PPH, which includes international powerhouses such as AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on par with U.S. behemoths.
Geopolitical Hedge: International diversification renders PPH less susceptible to U.S.-specific tariff risks or reforms.
Growth Exposure: Novo Nordisk&#8217;s dominance of GLP-1-based obesity treatment provides a high-growth component, although subject to some headwinds due to compounding alternatives in the U.S.
<h1 class="wp-block-heading">Volatility Ahead?</h1>
These ETF dynamics are unfolding against a backdrop of sweeping proposals and heightened industry-government tension. The Trump administration's <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">revived push to tether Medicaid drug prices to lower international benchmarks</a> has sent shockwaves through the pharmaceutical sector. Industry analysts estimate the pricing framework could erase as much as $1 trillion in revenue over a decade, according to Bloomberg.
Surprised by the White House&#8217;s latest move, drug industry executives have mounted a concerted lobbying effort, trying to keep the policy from taking hold in Congress. Although some Republican lawmakers, including Kentucky Rep. Brett Guthrie, have reaffirmed their opposition to global reference pricing, the proposal is still a live political threat, Bloomberg reported.
And adding to investor anxiety is Trump&#8217;s latest threat of<a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market"> sector-specific tariffs on drugs</a>. Although the Department of Commerce&#8217;s Section 232 investigation can take months, the threat of new import tariffs — particularly on Indian generics and contract-manufactured products — has already spilled over into related stocks. Insiders within the industry say the administration might move while there is a 90-day moratorium on reciprocal tariff imposition.
Not all of Washington&#8217;s signals are bearish, though. A recently signed executive order is intended to <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">lower FDA approval times for U.S. manufacturing plants</a> — potentially speeding up reshoring and encouraging investment in U.S.-based production. For more exposed domestic manufacturers and smaller company-focused ETFs such as XPH, this may be a long-term tailwind.
<h1 class="wp-block-heading">Proceed, But With Prescription-Strength Caution</h1>
For those looking for exposure to the pharma industry, ETFs are still an important tool — but their variations are more important than ever.
IHE provides stability but is heavily influenced by the success of U.S. policy.
XPH offers balanced exposure and is potentially more sensitive to reforms in domestic manufacturing.
PPH offers a global cushion, especially useful if U.S.-focused risks increase.
In the end, pharma ETFs&#8217; future may depend less on laboratory discoveries than on the political medicine doled out by Washington. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45259802/vistashares-launches-qusa-etf-targeting-15-annual-yield-with-quality-us-stocks-options-overlay">VistaShares Launches QUSA ETF, Targeting 15% Annual Yield With Quality U.S. Stocks, Options Overlay</a></li>
</ul>
Photo: Aria Armoko via Shutterstock

Sector ETFs

ETFs

Merrill Lynch Pharmaceutical HOLDRs Trust

VTRS

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables.
What Happened: On Wednesday, during Novo&#8217;s <a href="https://benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings">first quarter earnings</a> call, the company highlighted its upcoming oral weight loss drug, which CEO Lars Fruergaard calls &#8220;Wegovy in a pill,&#8221; and is currently under review by the U.S. Food and Drug Administration.
&#8220;If approved, this will be the first oral GLP-1 treatment for obesity in the United States,&#8221; Fruergaard said, adding that being first to market with a &#8220;known molecule, known efficacy, known safety&#8221; positions the company well in what he described as a smaller, but meaningful, segment of the market.
See More: <a href="https://www.benzinga.com/markets/equities/25/05/45275248/uber-ceo-dara-khosrowshahi-says-average-waymo-in-austin-is-busier-than-99-of-human-drivers">Uber CEO Dara Khosrowshahi Says &#8216;Average Waymo In Austin Is Busier Than 99%&#8217; Of Human Drivers</a>
Martin Lange, executive vice president of development at Novo, said the 25-milligram oral formulation &#8220;demonstrates an overall efficacy and safety profile similar to once-weekly injectable semaglutide 2.4 milligram.&#8221;
During the trial, adults struggling with obesity, who received 25 milligrams of oral semaglutide experienced &#8220;16.6% average weight loss,&#8221; Lange says, with one-third of participants experiencing weight loss of &#8220;20% of more.&#8221; Lange added that the FDA review is expected to conclude by late 2025 or early 2026.
Why It Matters: The company saw a <a href="https://benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings">big surge in Wegovy sales</a> during the first quarter, at $2.63 billion, up 85% year-over-year, as it gears up to launch the oral version of its drug.
This comes amid analyst predictions that rival Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) oral weight loss drugs can <a href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence">take share away</a> from Novo&#8217;s Semaglutide. 
During its first quarter, Novo Nordisk generated $10.9 billion in sales, missing consensus estimates at $11.64 billion, with a profit of $0.92 per share, beating estimates at $0.90. 
Price Action: The stock was up 1.90% on Wednesday, but is down 2.38% after hours following the company&#8217;s first quarter earnings release.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="137" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-1024x137.png" alt="" class="wp-image-907057" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-1024x137.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-768x103.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-1536x205.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM.png 1588w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
According to Benzinga Edge Stock Rankings, Novo Nordisk has an unfavorable price trend in the short, medium, and long term. For more insights, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a>.
Photo Courtesy: kikpokemon on Shutterstock.com
Read More: <a href="https://www.benzinga.com/markets/25/05/45274831/trump-tariff-pressure-reportedly-opens-global-doors-for-elon-musks-starlink-as-nations-rush-to-show-goodwill">Trump Tariff Pressure Reportedly Opens Global Doors For Elon Musk&#8217;s Starlink As Nations Rush To Show &#8216;Goodwill&#8217;</a>

Earnings

Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Wednesday reported first-quarter 2025 sales of roughly $10.89 billion (78.09 billion Danish kroner), missing the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $11.64 billion</a>.
Sales increased by 19% in Danish kroner and 18% at CER. In U.S. Operations, sales increased by 20% in Danish kroner and 17% at CER.
Sales in International Operations increased by 18% measured in Danish kroner and by 19% at CER. Sales growth has resulted in periodic supply constraints and related drug shortage notifications for certain products and geographies.
The weight loss drug maker <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915255" rel="noreferrer noopener">reported</a> Q1 adjusted EPS of 92 cents, beating the consensus of 90 cents.
The company reported an adjusted net profit of 30.3 billion in the quarter, which was up 15% year over year.
Ozempic&nbsp;<a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/5fa26f83-a579-42fc-a3bf-242fe76a5f3e" rel="noreferrer noopener">sales</a> increased 18% to 32.72 billion Danish kroner, and Wegovy sales jumped 85% to 17.36 billion Danish kroner.
The company added that the volume of compounded GLP-1s in the U.S. is estimated to have impacted the uptake of Wegovy prescriptions and the growth of the <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">branded obesity market</a> during the first quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45147328/cvs-caremark-to-place-novo-nordisks-wegovy-on-preferred-coverage-for-glp-1-weight-loss-treatment" rel="noreferrer noopener">CVS Caremark To Place Novo Nordisk&#8217;s Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment</a>
Insulin sales increased 4% to 14.9 billion Danish kroner, and Rare disease sales increased 5% to 4.62 billion Danish kroner.
Sales in Diabetes care increased by 10% and 8% at CER to 55.04 billion. Novo Nordisk&#8217;s global diabetes value market share decreased by 0.6% over the last 12 months to 33.3%, driven by market share losses in the U.S. and International Operations.
In IO countries, Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide is categorised under GLP-1 diabetes only in IQVIA data, despite having indications for Diabetes and Obesity in most launched countries.
In its earnings release, Novo Nordisk said it submitted a Supplemental New Drug Application (sNDA) to the U.S. FDA in February for the PDS290 device variant for Wegovy. The company expects the regulatory review to be completed around mid-year 2025.
In February 2025, Novo Nordisk submitted oral semaglutide 25 mg to the FDA, with the potential to be the first oral GLP-1 treatment for obesity.
The submission is based on OASIS 4, a 64-week efficacy and safety trial comparing once-daily oral semaglutide 25 mg to placebo in 307 adults with obesity or overweight with one or more comorbidities.
In adults with obesity or overweight, oral semaglutide 25 mg achieved a 16.6% weight loss from a baseline bodyweight of 105.9 kg compared to a 2.7% reduction with placebo.
Novo Nordisk expects the regulatory review to be completed around the turn of the year.
<h2 class="wp-block-heading">Guidance For 2025</h2>
Novo Nordisk lowered its 2025 sales <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">growth from 16%-24%</a> to 13%-21% at CER and operating profit growth of 16%-24%, down from 19%-27% at CER.
Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.
The updated sales outlook reflects lower-than-planned penetration of branded GLP-1 treatments in the U.S., impacted by compounded GLP-1s.
Price Action: At the last check on Wednesday, NVO stock was up 5.49% at $69.93 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Guidance

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook

Watching Novo Nordisk: Hearing Novo Nordisk Head Of U.S. Operations Says We Fully Expect The FDA To Enforce The Ban On Drug Compounding; We Will Continue To Fight Against Unlawful Compounding

Novo Nordisk shares are trading higher after the company reported better-than-expected Q1 EPS results.

Shares of Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY25 sales <a href="https://www.benzinga.com/quote/PRCH/earnings">guidance above estimates</a>.
Porch Group reported quarterly earnings of 8 cents per share which beat the analyst consensus estimate of a loss of 12 cents per share. The company reported quarterly sales of $104.75 million which beat the analyst consensus estimate of $79.44 million.
Porch Group shares jumped 21.4% to $7.70 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Magic Empire Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEGL#NASDAQ">MEGL</a>) rose 77.3% to $2.11 in pre-market trading.</li>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) surged 68.4% to $0.2730 in pre-market trading after jumping around 8% on Tuesday.</li>
<li>NetClass Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) gained 51.5% to $50.00 in pre-market trading after jumping over 162% on Tuesday.</li>
<li>Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) jumped 29.7% to $1.79 in pre-market trading after falling 5% on Tuesday.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) gained 28.3% to $0.3280 in pre-market trading.</li>
<li>CuriosityStream Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) surged 24.2% to $4.10 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter sales guidance above estimates.</li>
<li>AvidXchange Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) gained 19.3% to $9.78 in pre-market trading after the company announced it entered into a definitive agreement to be acquired by TPG in partnership with Corpay for a valuation of $2.2 billion.</li>
<li>Cantor Equity Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) climbed 18% to $34.57 in pre-market trading after dipping 14% on Tuesday.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) gained 7.9% to $71.50 in pre-market trading following first-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares dipped 62.5% to $0.1402 in pre-market trading after the company announced it voluntarily delisted from the Nasdaq.</li>
<li>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares fell 46.8% to $0.42 in pre-market trading after the company missed its first-quarter adjusted EPS estimate and announced it will not be providing FY25 guidance.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) shares fell 37.8% to $1.00 in pre-market trading. FOXO Technologies shares jumped 153% on Tuesday after the company announced that its Myrtle recovery centers subsidiary has seen over 400 patients since August 2023.</li>
<li>Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) fell 25.7% to $6.47 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>AIFU Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) declined 23.6% to $0.1719 in pre-market trading after jumping 82% on Tuesday.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares tumbled 20.6% to $37.10 in pre-market trading after the company reported a first-quarter adjusted EPS miss.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) fell 16.2% to $43.09 in pre-market trading after the company issued second-quarter sales guidance below estimates.</li>
<li>Lixiang Education Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) dipped 14.1% to $3.00 in pre-market trading after jumping 69% on Tuesday.</li>
<li>Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) fell 10.8% to $16.90 in today's pre-market trading after the company reported downbeat quarterly sales.</li>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) fell 7.6% to $12.70 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AIFU

AVDX

CNEY

CURI

FOXO

FRGT

LXEH

MEGL

NTCL

PRCH

RVLV

SRPT

UPST

VSTE

VSTS

Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) slashed its 2025 sales forecast Wednesday, citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments in the U.S. market due to competition from compounded versions of the drugs.
What Happened: The Danish pharmaceutical giant now expects sales growth of 13-21% at constant exchange rates, down from previous projections. Operating profit growth is now forecast at 16-24%.
&#8220;We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the U.S.,&#8221; said CEO Lars Fruergaard Jørgensen in the company&#8217;s first quarter earnings report.
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45244733/elon-musks-xai-teams-up-with-palantir-twg-global-as-alex-karp-backs-ai-push-in-financial-services">Elon Musk&#8217;s xAI Teams Up With Palantir, TWG Global As Alex Karp Backs AI Push In Financial Services</a>
Why It Matters: The headwinds come as weight-loss industry pioneer WW International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>), formerly known as WeightWatchers, filed for <a href="https://www.benzinga.com/markets/25/05/45243206/despite-bruce-galloways-pushback-on-bankruptcy-weightwatchers-enters-chapter-11-says-members-wont-be-affected">Chapter 11 bankruptcy protection this week</a>, highlighting the disruptive impact of GLP-1 drugs like Novo&#8217;s Wegovy and Ozempic.
Novo Nordisk faces additional market uncertainty as the President Donald Trump administration contemplates policies to match U.S. drug prices with <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">lower rates in other developed nations</a>. 
The company continues to expand its product pipeline, recently completing the REDEFINE 2 trial for CagriSema, which demonstrated 15.7% weight loss in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still expects to file for regulatory approval in the first quarter of 2026.
&#8220;With around 1 billion people living with obesity globally and only few million on treatment, Novo Nordisk continues the global roll-out of Wegovy,&#8221; the company stated.
Price Action: Novo Nordisk stock closed at $66.29 on Tuesday, down 4.09% for the day. In after-hours trading, the stock rose 1.37% to $67.20. Year to date, the stock has declined by 24.26%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45242461/donald-trumps-trade-war-sparks-first-major-us-china-talks-scott-bessent-jamieson-greer-to-meet-chinese-delegation-in-geneva">Scott Bessent To Meet Chinese Officials For Crucial Trade Talks In Switzerland: Trump Administration</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: JHVEPhoto / Shutterstock.com

Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed

Press Releases

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

Legal

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

NVO FINAL DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action – NVO

NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline

Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

NVO DEADLINE ALERT: Novo Nordisk (NVO) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 25th Deadline in Securities Class Action

Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – NVO

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Comments

Novo Nordisk

Noticias

Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL